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for the intervention and comparator arms were sourced from relevant clinical tri-
als; survival was assumed to follow an exponential distribution. Representative 
acquisition, administration, and monitoring costs were sourced from the litera-
ture and health technology assessment appraisals. The maximum CEP for each 
analogue was evaluated at two different willingness-to-pay (WTP) thresholds: 
£20,000/QALY and £50,000/QALY. All costs and outcomes were discounted at 
3.5%. RESULTS: The results from the early economic model suggested that neither 
pertuzumab nor trametinib would ever be a cost-effective therapy even at a WTP 
threshold of £50,000. However, at both WTP thresholds of £20,000 and £50,000/
QALY, idelalisib was projected to have a cost-effective price, which was similar 
to the current list price in the UK. CONCLUSIONS: These results demonstrate 
that neither pertuzumab nor trametinib have CEPs, while the CEP for idelalisib is 
similar to the UK launch price, demonstrating that add-on branded therapies co-
administered without anchors dosed to progression (here, rituximab) will permit 
higher prices while remaining cost-effective. This analysis highlights the utility 
of early economic models in evaluating potential pricing and HTA barriers early 
in the development process.
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OBJECTIVES: The purpose of this study was to evaluate the maximum cost-effective 
price (CEP) supported for innovative drugs co-administered with existing branded 
therapies. METHODS: An early economic model was constructed in Microsoft 
Excel using a three-state partitioned-survival approach. The intervention arm was 
assumed to be a hypothetical regimen consisting of an add-on drug and an anchor 
branded therapy, while the comparator consisted of the anchor therapy; both arms 
were dosed to progression. Three pricing scenarios were evaluated for the anchor: 
£1,000/month (low cost), £3,000/month (moderate cost), and £5,000/month (high 
cost). Other costs were sourced from a literature review; adverse event costs were 
not included. Progression-free survival (PFS) and overall survival (OS) were modelled 
assuming an exponential distribution; different median PFS and OS gains were 
evaluated to determine the maximum cost-effective price permitted for the add-on 
therapy. The maximum supported price was evaluated at two different willingness-
to-pay (WTP) thresholds: £20,000/QALY and £50,000/QALY. All costs and outcomes 
were discounted at 3.5%. RESULTS: For small gains in OS and PFS (< 3 months), the 
model projects that no CEP for the add-on would be supported at a WTP threshold 
of £20,000/QALY. When administered with a low-cost anchor, the add-on would 
be cost-effective at a WTP of £50,000/QALY with a price up to £583/month; when 
administered with a high-cost therapy, no CEP was supported. In order to sup-
port any CEP for the add-on, substantial gains in OS are required: for a PFS gain 
of 3 months, a gain of 6.9 months for OS would be required at a WTP of £50,000/
QALY. CONCLUSIONS: These results demonstrate that new drugs co-administered 
with anchor branded therapies require substantial OS gains to support cost-effective 
pricing, as these drugs are dosed to progression. This analysis highlights the utility 
of early economic models in evaluating potential pricing and HTA barriers early in 
the development process.
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OBJECTIVES: To evaluate a new empirical algorithm for selecting disease-
related medical billing codes associated with chronic lymphocytic leukemia 
(CLL). METHODS: Patients in the SEER-Medicare database with a CLL diagnosis 
(2002 to 2010) were age/gender matched to a non-cancer sample. A proprietary cod-
ing algorithm based on code frequency (sensitivity, specificity precision or accuracy) 
and cost was used to identify procedure (i.e., CPT and HCPCS) and diagnosis (ICD-
9-CM) codes that differed between the CLL and non-cancer groups. Summarized 
costs for claims with the empirically identified codes were compared to a traditional 
approach of identifying disease-related claims based on presence of a CLL diagnosis 
in the first diagnosis field. The code set was applied to a sample from a prior CLL 
study conducted with commercial claims to assess generalizability. RESULTS: The 
analysis evaluated 10,531 unique billing codes with total costs of > $1 billion (US; CLL 
58.3%; non-cancer 41.7%) for 7,050 age and gender matched SEER-Medicare subjects 
per group. The empirical algorithm found 333 codes that identified 25.0% of the CLL 
group costs as cancer-related. The traditional approach used claims that contained 
2,001 codes and identified a much lower 14.6%. Approximately 1% of costs were 
potentially misidentified in the non-cancer cohort, providing further confirmation 
of the codes selected by the empirical method. Qualitative review of codes revealed 
stronger content validity with the empirical approach compared to the traditional 
approach. Application of codes identified in the SEER-Medicare data to the com-
mercial database provided validation by identifying almost twice as many costs 
as the traditional approach with a 1% error rate. CONCLUSIONS: The traditional 
approach underreports costs and captures costs from procedure codes that do not 
appear to be cancer-related. Use of an empirical approach to identify disease-related 
diagnosis and procedure codes will increase content validity.
PCN101
hosPitAl utilizAtioN iN PAtiENts with mANtlE CEll lymPhomA
Belk K.1, Craver C.W.2
1MedAssets, Mooresville, NC, USA, 2MedAssets, Inc., Huntersville, NC, USA
OBJECTIVES: To examine hospital utilization in patients diagnosed with mantle 
cell lymphoma (MCL). METHODS: A retrospective cross-sectional study was con-
cTACE strategy was estimated to be 414 days whereas that of DEB TACE strategy was 
estimated to be 651 days. The total costs for cTACE strategy and DEB TACE strategy 
were EGP 420,529 and EGP 1,351,105 respectively. Thus the incremental cost effec-
tiveness ratio (ICER) for cTACE versus DEB TACE is EGP 3,926 per one day survival 
gained. The Deterministic sensitivity analysis demonstrated that survival associated 
by DEB TACE strategy and DEB-TACE operation costs have the greatest effect on the 
results. CONCLUSIONS: Results from this study suggest that employing a cTACE 
strategy is cost-effective intervention compared to DEB TACE in patients with hepa-
tocellular carcinoma based on the willingness to pay threshold stated by world health 
organization (3xGDP/capita) for low and middle income countries.
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OBJECTIVES: Pricing and reimbursement is typically approached product by prod-
uct, not in comparison across therapeutic areas in Peru. Within oncology, there are 
relatively few treatment options for advance stage cancer patients that have docu-
mented significant increases in overall survival (OS). Ipilumumab has been recently 
approved in Peru for the treatment of unresectable or metastatic melanoma. Given 
the rising costs of cancer care payers and physicians need to better understand 
the value of innovative oncology drugs for reimbursement decision making. This 
study assesses the cost per additional month of mean overall survival of ipilimumab 
and how this metric compares to other oncology agents approved in Peru in the 
metastatic setting. METHODS: We selected agents that received regulatory authori-
zation in the last 10 years in Peru and had phase 3 studies with OS as a primary or 
secondary objective. Mean OS was obtained from published literature. Drug prices 
were obtained from “observatorio de precios de DIGEMID” a public database. The 
economic value of each asset is presented in terms of cost per additional month of 
mean OS from a private healthcare payer perspective. The analysis uses the cost 
to treat to mean progression of each agent divided by the months of mean overall 
survival improvement using its current list price. All prices are in 2014 “nuevos 
soles” RESULTS: Seventeen drugs met inclusion criteria. Of these, 26 different indi-
cations were evaluated. The average cost per mean overall survival month gained 
was estimated at S/.57,178, range S/.3,108 – S/.264,764. Ipilimumab as first and sec-
ond line treatment for metastatic melanoma had an estimated cost per additional 
mean overall survival at S/.36,901 and S/.41,740 respectively. CONCLUSIONS: In 
this cost efficacy analysis, Ipilimumab´s cost per additional month of overall sur-
vival was estimated below the market average. At current private market prices 
Ipilimumab may offer good value for money.
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OBJECTIVES: Recent findings show that vaccinating older men who have sex with 
men (MSM) with history of high-grade anal intraepithelial neoplasia (HGAIN)–a 
precursor to anal cancer–with quadrivalent human papillomavirus (qHPV) vac-
cine was associated with 50% decrease in the hazards for recurrent or persistent 
HGAIN. We evaluated the long-term clinical and economic outcomes of adding 
qHPV vaccine to the HGAIN treatment regimen HGAIN in HIV-positive MSM aged ≥ 
27 years. METHODS: Using Markov model of anal histology in HIV-positive MSM we 
compared two strategies–no qHPV vaccination after treatment for HGAIN versus 
qHPV vaccination after treatment for HGAIN. The probability of anal intraepithelial 
neoplasia (AIN) progression was conditional on patients’ CD4 count. Model param-
eters, including baseline prevalence, disease transitions, costs, and utilities were 
either obtained from literature or calibrated using a natural history model of anal 
carcinogenesis. Model output included lifetime costs, quality-adjusted life years 
(QALYs), and lifetime risk of developing invasive cancer. Results from the healthcare 
perspective were presented in the forms of incremental cost-effectiveness ratios 
(ICERs) and decrease in lifetime risk of anal cancer. Deterministic and probabilistic 
sensitivity analyses were conducted on model parameters. RESULTS: Vaccination 
after treatment for HGAIN decreased the lifetime risk of anal cancer by 63% com-
pared to the no vaccination strategy. Vaccination resulted in the decrease in lifetime 
costs with increase in effectiveness by 0.16 QALYs. The predicted incidence of anal 
cancer after vaccination was almost one-third to that of the no vaccination strategy. 
The results were sensitive to the model parameters–progression from HGAIN to 
cancer, mortality attributed to anal cancer, cost of HGAIN treatment, and discount 
rate. CONCLUSIONS: Vaccinating the high-risk population of HIV-positive MSM aged 
≥ 27 after treatment for HGAIN is a cost-saving strategy. Expansion of current vac-
cination guidelines to include this population should be a priority.
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OBJECTIVES: The purpose of this study was to develop an early economic model to 
compare the maximum supported cost-effective prices (CEP) of recently launched 
co-administered branded products to their list prices in the UK. METHODS: An 
early economic model was constructed in Microsoft Excel using a three-state 
partitioned-survival approach. A pragmatic literature search was performed iden-
tified three co-administered branded therapies as case studies: pertuzumab + 
trastuzumab(+docetaxel) in HER2+ breast cancer, trametinib + dabrafenib in mela-
noma, and idelalisib + rituximab in chronic lymphocytic leukaemia; all therapies 
except rituximab were dosed to progression. Progression-free and overall survival 
